🇺🇸 FDA

Intelligence Platform

Patents

Browse 62 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12428470

Compositions containing activatable antibodies

CytomX Therapeutics, Inc. · Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139543

Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to de

CytomX Therapeutics, Inc. · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049505

Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and

CytomX Therapeutics, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11992528

Compositions and methods for conjugating activatable antibodies

CytomX Therapeutics, Inc. · Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11952427

Anti-CD40 antibodies and uses thereof

CytomX Therapeutics, Inc. · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890354

Activatable antibodies that bind epidermal growth factor receptor and methods thereof

CytomX Therapeutics, Inc. · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884746

Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods

CytomX Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11867695

Compositions and methods for detecting protease activity in biological systems

CytomX Therapeutics, Inc. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11859010

Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable anti

CytomX Therapeutics, Inc. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11814410

Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereo

CytomX Therapeutics, Inc. · Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11802158

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of

CytomX Therapeutics, Inc. · Granted Tue Oct 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11753466

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11667687

Masked activatable interferon constructs

CytomX Therapeutics, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548943

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of u

CytomX Therapeutics, Inc. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548944

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of u

CytomX Therapeutics, Inc. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472875

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of u

CytomX Therapeutics, Inc. · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472889

Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable anti

CytomX Therapeutics, Inc. · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306149

Anti-CD40 antibodies and uses thereof

CytomX Therapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11267896

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11180562

Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-r

CytomX Therapeutics, Inc. · Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11174316

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11168144

Activatable anti-PDL1 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11161906

Multispecific antibodies, multispecific activatable antibodies and methods of using the sa

CytomX Therapeutics, Inc. · Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117968

Activatable anti-CTLA-4 antibodies and uses thereof

CytomX Therapeutics, Inc. · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted